Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

Microbot Medical Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HINGHAM, MASS., NOV. 26, 2025 (GLOBE NEWSWIRE) -- MICROBOT MEDICAL INC. (NASDAQ: MBOT), DEVELOPER AND DISTRIBUTOR OF THE INNOVATIVE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM, ANNOUNCED THAT EMORY UNIVERSITY HOSPITAL, A NATIONALLY RECOGNIZED ACADEMIC MEDICAL CENTER IN ATLANTA, HAS BECOME THE FIRST HOSPITAL TO ADOPT LIBERTY FOR PATIENT CARE.

MICROBOT MEDICAL ANNOUNCES EMORY UNIVERSITY HOSPITAL AS THE FIRST HOSPITAL IN THE WORLD TO ADOPT THE NEW LIBERTY ENDOVASCULAR ROBOTIC SYSTEM

COMPANY COMPLETES THE REQUIRED INFRASTRUCTURE TO SUPPORT THE INTRODUCTION OF LIBERTY TO THE U.S. MARKET WITH THE HIRING OF THE CORE COMMERCIAL TEAM AND ESTABLISHING LOGISTIC PARTNERSHIP INTEREST AND OVERWHELMINGLY POSITIVE FEEDBACK FROM PHYSICIANS AND HOSPITAL ADMINISTRATORS AT RECENT MEETINGS VALIDATES LIMITED MARKET RELEASE OF LIBERTY  HINGHAM, MASS., NOV. 05, 2025 (GLOBE NEWSWIRE) -- MICROBOT MEDICAL INC. (NASDAQ: MBOT), DEVELOPER AND DISTRIBUTOR OF THE INNOVATIVE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM, ANNOUNCED THAT ITS LIBERTY SYSTEM, THE FIRST FDA CLEARED SINGLE-USE, REMOTELY OPERATED ROBOTIC SYSTEM FOR PERIPHERAL ENDOVASCULAR PROCEDURES, IS NOW COMMERCIALLY AVAILABLE IN THE U.S. THE LIMITED MARKET RELEASE (LMR) WILL INTRODUCE LIBERTY TO SELECTED HIGH PROCEDURE VOLUME REGIONS WHERE THE COMPANY ALREADY EXPERIENCED PRELIMINARY DEMAND FOR LIBERTY.

MICROBOT MEDICAL COMMENCES THE LIMITED MARKET RELEASE OF ITS LIBERTY ENDOVASCULAR ROBOTIC SYSTEM IN THE U.S.

FIRST U.S. BASED MEDICAL MEETING PRESENCE POST-FDA CLEARANCE WILL ALLOW THE COMPANY TO COMMERCIALLY ENGAGE FUTURE POTENTIAL USERS OF THE LIBERTY SYSTEM

MICROBOT MEDICAL TO COMMERCIALLY DEBUT THE LIBERTY SYSTEM AT THE SYMPOSIUM ON CLINICAL INTERVENTIONAL ONCOLOGY ANNUAL MEETING

THE EXPERIENCED MEDTECH LOGISTICS PROVIDER WILL HELP ENSURE EFFECTIVE AND EFFICIENT INVENTORY MANAGEMENT AND CUSTOMER SUPPORT THE COMPANY IS ON TRACK TO COMMENCE THE LAUNCH OF LIBERTY DURING Q4 THIS YEAR

MICROBOT MEDICAL SECURES U.S. BASED LOGISTICS PARTNER TO SUPPORT THE COMMERCIALIZATION OF ITS LIBERTY ENDOVASCULAR ROBOTIC SYSTEM

$25.2 MILLION IN FIRST CLOSING, $1.2 MILLION IN SECOND CLOSING AND $2.8 MILLION IN THIRD AND FINAL CLOSING, WITH UP TO AN ADDITIONAL APPROXIMATELY $63 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM PREFERRED INVESTMENT OPTIONS $25.2 MILLION IN FIRST CLOSING, $1.2 MILLION IN SECOND CLOSING AND $2.8 MILLION IN THIRD AND FINAL CLOSING, WITH UP TO AN ADDITIONAL APPROXIMATELY $63 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM PREFERRED INVESTMENT OPTIONS

MICROBOT MEDICAL ANNOUNCES FINAL CLOSING OF EXERCISE OF OUTSTANDING PREFERRED INVESTMENT OPTIONS OF UP TO $92.2 MILLION IN GROSS PROCEEDS

COMMERCIAL FOCUS REMAINS ON U.S. MARKET AS IT CONTINUES TO EXPLORE CERTAIN GLOBAL MARKETS THAT ACCEPT FDA CLEARED DEVICES PROTECTING ITS INNOVATIVE TECHNOLOGY REMAINS A PRIORITY AND MOMENTUM INCREASING AS GLOBAL JURISDICTIONS ACKNOWLEDGE THE UNIQUENESS OF THE LIBERTY SYSTEM HINGHAM, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- MICROBOT MEDICAL INC. (NASDAQ: MBOT), DEVELOPER, MANUFACTURER AND DISTRIBUTER OF THE INNOVATIVE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM, TODAY ANNOUNCED THAT THE JAPANESE PATENT OFFICE HAS GRANTED THE COMPANY ITS FIRST PATENT IN JAPAN, COVERING THE CORE LIBERTY SYSTEM TECHNOLOGY, SUCH AS A COMPACT ROBOTIC DEVICE FOR DRIVING AND MANIPULATING MOVEMENT OF AT LEAST ONE ELONGATE SURGICAL TOOL.

MICROBOT MEDICAL RECEIVES FIRST PATENT IN JAPAN AS IT CONTINUES TO BROADEN ITS GLOBAL INTELLECTUAL PROPERTY PORTFOLIO

LIVESTREAM INTERVIEW CAN BE VIEWED ON SEPTEMBER 24TH AT 10:45AM ET AT BENZINGA ALL ACCESS LIVE LIVESTREAM INTERVIEW CAN BE VIEWED ON SEPTEMBER 24TH AT 10:45AM ET AT BENZINGA ALL ACCESS LIVE

MIOCRBOT MEDICAL CEO TO DISCUSS RECENT FDA CLEARANCE OF THE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM

$25.2 MILLION IN FIRST CLOSING AND $4 MILLION IN SECOND CLOSING, WITH UP TO AN ADDITIONAL APPROXIMATELY $63 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM PREFERRED INVESTMENT OPTIONS $25.2 MILLION IN FIRST CLOSING AND $4 MILLION IN SECOND CLOSING, WITH UP TO AN ADDITIONAL APPROXIMATELY $63 MILLION OF POTENTIAL AGGREGATE GROSS PROCEEDS UPON THE EXERCISE IN FULL OF SHORT-TERM PREFERRED INVESTMENT OPTIONS

MICROBOT MEDICAL ANNOUNCES FIRST CLOSING OF EXERCISE OF OUTSTANDING PREFERRED INVESTMENT OPTIONS OF UP TO $92.2 MILLION IN GROSS PROCEEDS

BRAINTREE, MASS., SEPT. 15, 2025 (GLOBE NEWSWIRE) -- MICROBOT MEDICAL INC. (NASDAQ: MBOT) (MICROBOT OR THE COMPANY), TODAY ANNOUNCED THE ENTRY INTO DEFINITIVE AGREEMENTS FOR THE EXERCISE OF CERTAIN OUTSTANDING PREFERRED INVESTMENT OPTIONS TO PURCHASE UP TO AN AGGREGATE OF 13,989,115 SHARES OF COMMON STOCK.

MICROBOT MEDICAL ANNOUNCES EXERCISE OF OUTSTANDING PREFERRED INVESTMENT OPTIONS FOR UP TO $92.2 MILLION IN GROSS PROCEEDS

HINGHAM, MASS., SEPT. 09, 2025 (GLOBE NEWSWIRE) -- MICROBOT MEDICAL INC. (NASDAQ: MBOT), DEVELOPER AND MANUFACTURER OF THE INNOVATIVE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM, TODAY ANNOUNCED THAT HAREL GADOT, CEO, PRESIDENT & CHAIRMAN, WILL HIGHLIGHT THE RECENT FDA CLEARANCE OF THE LIBERTY SYSTEM, THE FIRST SINGLE-USE, REMOTELY OPERATED ROBOTIC SYSTEM FOR PERIPHERAL ENDOVASCULAR PROCEDURES, AT THE H.C.

REMINDER: MICROBOT MEDICAL TO HIGHLIGHT FDA 510(K) CLEARANCE OF THE LIBERTY ENDOVASCULAR ROBOTIC SYSTEM AT THE H.C. WAINWRIGHT ANNUAL INVESTOR CONFERENCE

Microbot Medical Inc.

MBOT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Microbot Medical Inc.

MBOT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MBOT